A Systematic Review of Adherence With Medications for Diabetes

OBJECTIVE —The purpose of this study was to determine the extent to which patients omit doses of medications prescribed for diabetes. RESEARCH DESIGN AND METHODS —A literature search (1966–2003) was performed to identify reports with quantitative data on adherence with oral hypoglycemic agents (OHAs) and insulin and correlations between adherence rates and glycemic control. Adequate documentation of adherence was found in 15 retrospective studies of OHA prescription refill rates, 5 prospective electronic monitoring OHA studies, and 3 retrospective insulin studies. RESULTS —Retrospective analyses showed that adherence to OHA therapy ranged from 36 to 93% in patients remaining on treatment for 6–24 months. Prospective electronic monitoring studies documented that patients took 67–85% of OHA doses as prescribed. Electronic monitoring identified poor compliers for interventions that improved adherence (61–79%; P CONCLUSIONS —This review confirms that many patients for whom diabetes medication was prescribed were poor compliers with treatment, including both OHAs and insulin. However, electronic monitoring systems were useful in improving adherence for individual patients. Similar electronic monitoring systems for insulin administration could help healthcare providers determine patients needing additional support.

[1]  P. Donnan,et al.  Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[2]  J. Weissberg-Benchell,et al.  Adolescent Diabetes Management and Mismanagement , 1995, Diabetes Care.

[3]  R. Rosenheck,et al.  Enhancing medication compliance for people with serious mental illness. , 1999, The Journal of nervous and mental disease.

[4]  J. LeLorier,et al.  Predictors of persistence of use of the novel antidiabetic agent acarbose. , 2001, Archives of internal medicine.

[5]  John D. Voss,et al.  The association between diabetes metabolic control and drug adherence in an indigent population. , 2002, Diabetes care.

[6]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[7]  A. Paes,et al.  Impact of Dosage Frequency on Patient Compliance , 1997, Diabetes Care.

[8]  B. Mason,et al.  Assessment of Sulfonylurea Adherence and Metabolic Control , 1995, The Diabetes educator.

[9]  M. Tran,et al.  Effects of Once-Daily and Twice-Daily Dosing on Adherence With Prescribed Glipizide Oral Therapy for Type 2 Diabetes , 2002, Southern medical journal.

[10]  G. Nichols,et al.  Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. , 1999, Clinical therapeutics.

[11]  C. Kozma,et al.  Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age, Gender, and Race , 1999, The Diabetes educator.

[12]  Joyce A. Cramer,et al.  Patient Compliance in Medical Practice and Clinical Trials , 1991 .

[13]  P. Donnan,et al.  Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[14]  G. Dailey,et al.  Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. , 2001, Clinical therapeutics.

[15]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[16]  G. Kephart,et al.  Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada , 2002, Journal of clinical pharmacy and therapeutics.

[17]  S. Greene,et al.  Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus , 1997, The Lancet.

[18]  Judith Nowak.  Depth-Psychological Under-standing: The Methodologic Grounding of Clinical Interpretations. , 1999 .

[19]  J. Avorn,et al.  Persistence of use of lipid-lowering medications: a cross-national study. , 1998, JAMA.

[20]  B. Mason,et al.  Pharmacists' Interventions Using an Electronic Medication-Event Monitoring Device'S Adherence Data versus Pill Counts , 1993, The Annals of pharmacotherapy.

[21]  D. Berlowitz,et al.  Differential Adoption of Pharmacotherapy Recommendations for Type 2 Diabetes by Generalists and Specialists , 2003, Medical care research and review : MCRR.

[22]  M. Burnier,et al.  Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions , 2001, Journal of hypertension.

[23]  E. Walker,et al.  Understanding and enhancing adherence in adults with diabetes , 2003, Current diabetes reports.

[24]  J. Menzin,et al.  Potential short-term economic benefits of improved glycemic control: a managed care perspective. , 2001, Diabetes care.

[25]  PDB4: OBTAINING QUALITY REAL-WORLD TREATMENT DATA FOR ECONOMIC MODELS: METHODOLOGY AND RESULTS OF A WOUND CARE MEDICAL RECORD ABSTRACTION STUDY , 2003 .

[26]  W. Katon,et al.  Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. , 2000, Archives of internal medicine.

[27]  J. Cramer.  Enhancing Patient Compliance in the Elderly , 1998, Drugs & aging.

[28]  B. Anderson,et al.  Insulin Omission in Women With IDDM , 1994, Diabetes Care.

[29]  J. Mccombs,et al.  Compliance with Sulfonylureas in a Health Maintenance Organization: A Pharmacy Record–Based Study , 1999, The Annals of pharmacotherapy.

[30]  C. Rand,et al.  Improving inhaler adherence in a clinical trial through the use of the nebulizer chronolog. , 1993, Chest.

[31]  Caitlin E. Ryan,et al.  Electronic monitoring and counseling to improve medication adherence. , 2004, Behaviour research and therapy.

[32]  J. Cramer.  Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. , 1998, The American journal of managed care.

[33]  S. Johnson.  Methodological Issues in Diabetes Research: Measuring adherence , 1992, Diabetes Care.

[34]  C. Schmid,et al.  Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. , 2002, Diabetes care.

[35]  J. Wogen,et al.  Utilization of oral hypoglycemic agents in a drug-insured U.S. population. , 2001, Diabetes care.

[36]  J. Cramer,et al.  How often is medication taken as prescribed? A novel assessment technique. , 1989, JAMA.

[37]  D. Grobbee,et al.  Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? , 2003, Pharmacoepidemiology and drug safety.

[38]  Joyce A. Cramer,et al.  Partial Medical Compliance: The Enigma in Poor Medical Outcomes , 1995 .

[39]  A. Vanderplas,et al.  Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. , 2002, Clinical therapeutics.

[40]  A R Feinstein,et al.  On white-coat effects and the electronic monitoring of compliance. , 1990, Archives of internal medicine.

[41]  Caitlin E. Ryan,et al.  Neuropsychological Correlates of Suboptimal Adherence to Metformin , 2003, Journal of Behavioral Medicine.